Co-morbidities

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano, et al

Giuseppe Rosano , David Quek , Felipe Martínez ,

Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure

John JV McMurray,

Ovidiu Chioncel , Sean P Collins , Andrew P Ambrosy , et al

The PRESERVED-HF Study

Mikhail Kosiborod,

Jelena Celutkiene , Mindaugas Balčiūnas , Denis Kablučko , et al

Rami Khayat , Andrew Pederzoli , William T Abraham ,

Carine E Hamo , Michelle W Bloom ,

Saumil R Shah , Sergio Waxman , William H Gaasch ,

Eilidh Hill , Jackie Taylor ,

Karl-Heinz Kuck, Gian-Battista Chierchia, Ross Hunter, et al

Umar Ismail , Kiran Sidhu , Shelley Zieroth ,

About

Comorbidities frequently accompany chronic heart failure, contributing to increased morbidity and mortality, and an impaired quality of life. Extreme comorbidity is significantly more common in patients with chronic heart failure due to left ventricular systolic dysfunction. The efficient management of such complexity requires the integration of general and specialist expertise.

Videos

Andrew JS Coats, Stefan Anker,

Watch Now

Carlos Juanatey,

Watch Now

Stylianos Tzeis,

Watch Now

Yassir Javaid,

Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure

John JV McMurray,

Lars H Lund, James L Januzzi, Justin Ezekowitz, et al

EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

Shelley Zieroth, Kamlesh Khunti, Hiddo Lambers Heerspink, et al

Association Between AID/FID with Incident CV Disease and Mortality

Benedikt Schrage,

The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

The PRESERVED-HF Study

Mikhail Kosiborod,

Karl-Heinz Kuck, Gian-Battista Chierchia, Ross Hunter, et al

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano, et al

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

End of Year COVID update with Dr Mikhail Kosiborod and Dr Shelley Zieroth

Mikhail Kosiborod, Shelley Zieroth,

Year End Video With Dr Mikhail Kosiborod And Dr Silvio Inzucchi

Mikhail Kosiborod, Silvio Inzucchi,

Ileana L Piña, Shelley Zieroth,

Andrew JS Coats, Harriette Van Spall, Faiez Zannad, et al

Shelley Zieroth, Stefan Anker,

EASD 2019: The DEFINE-HF trial - Dr Mikhail N Kosiborod

Mikhail Kosiborod,

Videos

Andrew JS Coats, Stefan Anker,

Watch Now

Carlos Juanatey,

Watch Now

Stylianos Tzeis,

Watch Now

Yassir Javaid,

Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure

John JV McMurray,

Lars H Lund, James L Januzzi, Justin Ezekowitz, et al

EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

Shelley Zieroth, Kamlesh Khunti, Hiddo Lambers Heerspink, et al

Association Between AID/FID with Incident CV Disease and Mortality

Benedikt Schrage,

Kausik (Kosh) Ray, Lale Tokgözoğlu, Maciej Banach, et al

John JV McMurray, Stefan Anker, Melanie Davies, et al

The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

The PRESERVED-HF Study

Mikhail Kosiborod,

Karl-Heinz Kuck, Gian-Battista Chierchia, Ross Hunter, et al

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

ACC 2021 Discussion: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF, Including HFpEF

Deepak L Bhatt, Harriette Van Spall,

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano, et al

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

Su Down,

James L Januzzi, Akshay S Desai, Andrew JS Coats, et al

Stephen Fishbane, Adeera Levin, Kieran McCafferty , et al

Carol Pollock, Mark Petrie, David Cherney , et al

End of Year COVID update with Dr Mikhail Kosiborod and Dr Shelley Zieroth

Mikhail Kosiborod, Shelley Zieroth,

Year End Video With Dr Mikhail Kosiborod And Dr Silvio Inzucchi

Mikhail Kosiborod, Silvio Inzucchi,

Ileana L Piña, Shelley Zieroth,

AHA 2020 Discussion: The SOLOIST-WHF Study

Harriette Van Spall, Deepak L Bhatt,

AHA 2020: EMPA-TROPISM Trial Results — Dr Juan Badimon

Juan Badimon ,

AHA 2020 Discussion: Analysis from the EMPEROR-Reduced Study — Drs Javed Butler & Harriette Van Spall

Harriette Van Spall, Javed Butler,

Articles

Medical Treatment of HFrEF in the Elderly

Ivan Milinkovic

,

Marija Polovina

,

Andrew JS Coats

,

Giuseppe Rosano

,

Petar M Seferovic

,

Published:

09 May 2022

Citation:

Cardiac Failure Review 2022;8:e17.

DOI:

https://doi.org/10.15420/cfr.2021.14
  • Views: Views 569
  • Downloads: Downloads 51

Heart Failure Therapy in Older Patients

Davide Stolfo

,

Gianfranco Sinagra

,

Gianluigi Savarese

,

Published:

28 April 2022

Citation:

Cardiac Failure Review 2022;8:e16.

DOI:

https://doi.org/10.15420/cfr.2021.34
  • Views: Views 311
  • Downloads: Downloads 33

The Impact of Frailty and Comorbidities on Heart Failure Outcomes

Thomas Salmon

,

Hani Essa

,

Behnam Tajik

,

Masoud Isanejad

,

Asangaedem Akpan

,

Rajiv Sankaranarayanan

,

Published:

21 March 2022

Citation:

Cardiac Failure Review 2022;8:e07.

DOI:

https://doi.org/10.15420/cfr.2021.29
  • Views: Views 314
  • Downloads: Downloads 24

Iron Deficiency and Heart Failure

Pieter Martens

,

Published:

16 March 2022

Citation:

Cardiac Failure Review 2022;8:e06.

DOI:

https://doi.org/10.15420/cfr.2021.26
  • Views: Views 556
  • Downloads: Downloads 63